Back to search
Atypical Hemolytic Uremic Syndrome (aHUS)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Atypical Hemolytic Uremic Syndrome (aHUS) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Atypical Hemolytic Uremic Syndrome (aHUS) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aH…
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study parti…
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic sy…
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases…
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed…
This project aims to identify, through RNA-Seq technology, the genetic alterations underlying undiagnosed rare diseases in pediatric and adult patients with ear…
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatme…
This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric…